LGC LTD.

Company Overview

LGC Group markets specialized oligonucleotides, oligo synthesis reagents, and instruments through its Nucleic Acid Chemistry (NAC) business. Synthesis reagents include controlled pore glass supports; phosphonamidites; nucleosides; carbohydrates; and fluorescent reagents markets.

In September 2018, LGC launched its Biosearch Technologies division, which integrated its nucleic acid reagents and tools into a comprehensive offering. This division, located in Petaluma, Calif., focuses on oligonucleotides and enzymes. In March 2020 LGC Biosearch was validated at the U.S. Centers for Disease Control and Prevention and its kits were approved for emergency use in the detection of SARS-CoV-2, the virus that causes COVID-19.

In May 2018, LCG acquired BioAutomation, which manufactures oligo synthesizers under the MerMade brand. This acquisition helped provide a more complete solution to LGC’s oligonucleotide reagents customers as well as enhance the automation of LGC’s oligo manufacturing processes.

In February 2018, LGC acquired Lucigen, expanding its business in the NGS and gene editing businesses. Lucigen markets NGS kits, enzymes, competent cells, and cloning systems.

In November 2018, LGC acquired SeraCare Life Sciences, which markets quality control products for infectious disease testing and NGS. SeraCare’s Seraseq clinical genomics products are complementary to LGC’s oligonucleotides platforms.

LGC is a key corporate partner in a European NGS initiative, the European Advanced Infrastructure for Innovative Genomics (EASI-Genomics). EASI-Genomics is funded by the EU’s Horizon 2020 program and has a goal of providing free access to NGS technologies and services to European industrial and academic researchers.

In September 2022, LGC expanded its market presence by opening a state-of-the-art facility at the Oxford Technology Park to develop an advanced workflow applications laboratory for LGC Biosearch Technologies.

Financial Highlights (FY 2023)

Company's Business Segments

• Genomics : The segment includes LGC Biosearch Technologies (Nucleic acid production, Molecular biology, Complete PCR workflow solutions) and LGC Axolabs (high-end discovery and pre to late clinical-stage solutions).
• Quality Assurance : The segment comprises LGC Standards, LGC Clinical Diagnostics, LGC Assure, and National Laboratories and Science.